1. Platz Tolremo therapeutics AG
In 2018, over 2.4 million people died from cancer in the USA and Europe alone. This is owed to the fact that the eect of cancer drugs is rarely durable – the development of drug resistance is a major limiting factor to the survival of cancer patients. With continuing drug treatment, cancer cells accumulate irreversible, resistance-causing mutations that eventually lead to therapy failure. Once a tumor is drug resistant, further treatment options are very limited.
What we do
TOLREMO therapeutics AG is an ETH spin-o that was founded in 2017 to translate a cutting-edge scientic discovery into a life-saving clinical solution. We are dedicated to developing resistance-preventing therapies that can be combined with existing cancer drugs to boost their long-term eectiveness. Our molecules eradicate those cancer cells that are predisposed to develop irreversible drug resistance, but have not yet done so.
Based on our scientic innovation, we built a proprietary drug resistance screening platform that acts as TOLREMO’s discovery engine to identify resistance-preventing compounds and novel drug targets. Within the two years since foundation, the company has already developed two novel chemical classes (TT125 and TT5180) that eventually can be used to make existing cancer drugs work better and patients live longer.
www.tolremo.com
info@tolremo.com
TOLREMO therapeutics AG is an ETH spin-o that was founded in 2017 to translate a cutting-edge scientic discovery into a life-saving clinical solution. We are dedicated to developing resistance-preventing therapies that can be combined with existing cancer drugs to boost their long-term eectiveness. Our molecules eradicate those cancer cells that are predisposed to develop irreversible drug resistance, but have not yet done so.
Based on our scientic innovation, we built a proprietary drug resistance screening platform that acts as TOLREMO’s discovery engine to identify resistance-preventing compounds and novel drug targets. Within the two years since foundation, the company has already developed two novel chemical classes (TT125 and TT5180) that eventually can be used to make existing cancer drugs work better and patients live longer.
www.tolremo.com
info@tolremo.com
2. Platz Kitro
Two thirds of all food that is thrown away could have been avoided. A big portion of this waste is contributed by the tourism and hospitality industry leading to the depletion of natural resources such as water, land and energy. Not only does this have detrimental impacts on the environment but for food and beverage (F&B) businesses avoidable food waste also leads to unnecessary costs in food, labor and disposal. Switzerland’s foodservice industry alone is responsible for 290 000 tons of food waste costing the industry 1 billion francs annually (BAFU, 2019). Current solutions to measure food waste require sta to manually track every item once it is thrown away adding more work and interrupting the sta’s work ow.
Automated measurement
KITRO tackles this problem by providing restaurants, hotels and canteens with an innovative solution to automatically measure their waste. Using an IoT-device (scale, camera) and an image processing and machine learning software in the backend, food waste data is automatically tracked and analyzed. Customers pay a monthly subscription and receive actionable insights in form of an online dashboard on their waste allowing them to quickly understand their main operational ineciencies. Combining this data with goal setting meetings and food waste reduction methods enables them to decrease their avoidable food waste while increasing their performance and resource eciency.
www.kitro.ch
info@kitro.ch
KITRO tackles this problem by providing restaurants, hotels and canteens with an innovative solution to automatically measure their waste. Using an IoT-device (scale, camera) and an image processing and machine learning software in the backend, food waste data is automatically tracked and analyzed. Customers pay a monthly subscription and receive actionable insights in form of an online dashboard on their waste allowing them to quickly understand their main operational ineciencies. Combining this data with goal setting meetings and food waste reduction methods enables them to decrease their avoidable food waste while increasing their performance and resource eciency.
www.kitro.ch
info@kitro.ch
3. Platz Advanced Osteotomy Tools - AOT
CARLO® steht für «Cold Ablation Robot-guided Laser Osteotome». Es ermöglicht eine 100-Prozent-digitale Lösung für Knochenschnitte von der Planung bis zur Durchführung. Das CARLO®-System besteht aus einem taktilen und zertizierten Medizinal-Roboter und einem Roboterkopf, der einen speziell entwickelten Knochenschneidlaser mit integriertem Navigationssystem enthält. Das Spezielle; CARLO® bringt keine physischen Instrumente in den Patienten ein und kann im Notfall mit Lichtgeschwindigkeit gestoppt werden. Das ist weltweit einzigartig.
Bei Laserschnitten mit dem CARLO® bleibt die Knochenbiologie intakt und die «Schnittabfälle», die mit herkömmlichen Instrumenten in die Blutkanäle gedrückt werden, werden ausgeschleudert. Dies führt zu einer besseren Durchblutung und entsprechend schnelleren Heilung. Weitere Vorteile sind die beliebige Schnittgeometrie, die es dem Arzt ermöglicht, bioresorbierbare Implantate anstelle von massiven Metallimplantaten zu verwenden. Das Schneideinstrument, der Laser, ist immer scharf und steril. Heute üblicherweise verwendete Schnittschablonen sind nicht nötig.
AOT ist überzeugt, dass nicht nur der eigentliche Knochenschnitt mit CARLO® deutlich verbessert wird, sondern das auf der CARLO®-Plattform auch weitere ergänzende Technologien in den nächsten Jahren zum Einsatz kommen werden. Ein Beispiel dafür ist die «Echtzeit-Gewebeanalyse» bei Tumoreingrien. CARLO® ist momentan für gesichtschirurgische Eingrie in der klinischen Testung an den Universitätsspitälern Basel und Wien.
www.aot.swiss
info@aot.swiss
AOT ist überzeugt, dass nicht nur der eigentliche Knochenschnitt mit CARLO® deutlich verbessert wird, sondern das auf der CARLO®-Plattform auch weitere ergänzende Technologien in den nächsten Jahren zum Einsatz kommen werden. Ein Beispiel dafür ist die «Echtzeit-Gewebeanalyse» bei Tumoreingrien. CARLO® ist momentan für gesichtschirurgische Eingrie in der klinischen Testung an den Universitätsspitälern Basel und Wien.
www.aot.swiss
info@aot.swiss